Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the concentration of afamelanotide in serum after the administration of afamelanotide in adolescent and adult EPP patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06388642
Study type Interventional
Source Clinuvel Pharmaceuticals Limited
Contact Head of Clinical Operations
Phone +441372860765
Email mail@clinuvel.com
Status Recruiting
Phase Phase 1/Phase 2
Start date March 7, 2024
Completion date October 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT00979745 - Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP) Phase 3
Active, not recruiting NCT05308472 - Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP Phase 2
Completed NCT00004831 - Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria N/A
Completed NCT05572125 - Iron Therapy in Erythropoietic Protoporphyria
Completed NCT01605136 - Phase III Confirmatory Study in Erythropoietic Protoporphyria Phase 3
Completed NCT01422915 - Sorbent Therapy of the Cutaneous Porphyrias Phase 2/Phase 3
Completed NCT04053270 - Multicentre Phase III Erythropoietic Protoporphyria Study Phase 3
Completed NCT00004940 - Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria Phase 3
Recruiting NCT05020184 - Effect of Oral Cimetidine in the Protoporphyrias Phase 2
Completed NCT01688895 - Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact
Completed NCT04578496 - A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP) Phase 3
Recruiting NCT00206869 - Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic Protoporphyria N/A
Recruiting NCT05780840 - Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria N/A
Completed NCT02979249 - Oral Iron for Erythropoietic Protoporphyrias N/A
Enrolling by invitation NCT05883748 - Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP Phase 2/Phase 3
Completed NCT01097044 - Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) Phase 2
Completed NCT03682731 - Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria